Science of Aging: A Physiological & Translational PerspectiveAndy Henton2021-04-20T23:24:38-04:00
Science of Aging: A Physiological & Translational Perspective
The American Physiological Society (APS), Alliance for Aging Research (AAR), and InsideScientific are pleased to announce a joint webinar series covering fundamental principles, late-breaking research and novel discoveries in the field of aging science.
This program will include a number of live scientific lectures, including top science from leading researchers around the world, and “Technology & Methods” sessions focused on laboratory innovations and fundamental methods central to aging research and related models of disease.
Sessions in this webinar series are FREE to attend and we invite you to register by clicking the button below or by visiting https://bit.ly/AgingSeries2021
Musculoskeletal Composition, Strength and Sarcopenia
Neurodegeneration & Alzheimer’s Disease
Exercise Mitigated Aging
Aging & Bone Health
Cardiovascular and Vascular Maintenance & Renewal
Comparative Physiology of Aging
Aging and Diabetes
Vaccination and COVID-19 in the Elderly
Targeting Biological Aging: A New Paradigm for 21st Century Medicine
WED, APR 21, 2021 – UPCOMING
Biological age is the greatest risk factor for nearly every major cause of death and disability, including COVID-19. Yet, traditional biomedical research and clinical approaches have generally focused on waiting until people are sick and treating individual diseases one at a time. Attempts to cure age-related diseases have proven unsuccessful, and the impact of “disease-first” approaches continue to be incremental. Recent advances in understanding them mechanisms linking biological aging to disease, or geroscience, have identified interventions that directly target the molecular hallmarks of aging. Unlike disease-specific approaches, such interventions have the potential to prevent multiple diseases of aging simultaneously, thereby greatly enhancing healthspan and lifespan for most individuals.
During this webinar, Dr. Matt Kaeberlein will provide an overview of translational geroscience, which he believes will become the paradigm for the practice of medicine in the 21st century. He will also discuss recent work with one such intervention, the drug rapamycin, and its potential to enhance healthspan in companion dogs and people.
The Challenges of Sarcopenia: Definition, Underlying Mechanisms, Interventions, and Outcomes
WED, MAY 19, 2021 – UPCOMING
During this webinar, Drs. Peterson and Guralnik will discuss sarcopenia, the physiological mechanisms underlying the disease, and the current avenues of treatment and assessment that are being researched and developed for patients.
Sarcopenia is the age-related loss of muscle that causes decreased strength and functional limitations. Muscle loss occurs universally in people as we age, but some people lose muscle at an accelerated rate compared to others. While chronic disease can cause sarcopenia, it can also result from a sedentary lifestyle, hospitalizations and extended bed rest due to other conditions.
A gradual decline in muscle mass and strength begins around 30 years of age with this condition, and annual losses get larger throughout life. The self-reporting of functional difficulties to health care providers may give an indication that sarcopenia is present, but a more precise definition is needed for research and clinical use.
Efforts made in Europe and the US have used grip strength, gait speed and lean mass to define sarcopenia, but these definitions lead to large differences in prevalence rate and discordance in who is labelled as “sarcopenic”. To assess this condition, lean mass as measured by dual x-ray absorptiometry (DXA) may not accurately reflect actual muscle mass, but a new technique using dilution of deuterium-labelled creatine may prove to be superior in clinically diagnosing sarcopenia. Currently, a consensus has not been reached on the clinical outcome assessments that can be used by regulatory agencies to judge the effectiveness of drugs for sarcopenia.
A number of potential interventions are being explored to treat sarcopenia in older people, but no drugs are currently approved for this condition. The antidiabetic drug metformin shows promise in preventing many age-associated conditions, but appears to blunt the benefits of exercise on muscle. Senolytic drugs, which clear senescent cells, may improve muscle repair following injury preferentially in older individuals.
Experimental Muscle Mechanics in Aging and Disease
WED, JUN 2, 2021 – UPCOMING
The focus of this webinar is on the mechanisms underlying muscle impairment associated with aging and age-related diseases. This research evaluates the regulation of muscle contraction at the motor protein, single muscle fiber, and whole muscle levels using in vitro, in situ and in vivo methods in experimental and clinical settings. Specifically, Dr. Qaisar is interested in the contribution(s) of muscle SR stress and calcium dysregulation to loss of muscle mass and strength. Reduced calcium uptake by muscle SR plays a pivotal role in muscle impairment in aging while boosting SR calcium uptake with pharmacological activators can partially restore muscle mass and strength. Matt will share a technical overview of the experimental equipment used in this research. He will discuss the design, component functionality, and that applications that can be explored with this system. He will also share some valuable insights into the parameters that can be measured and the data that can be produced with various experimental designs.
Rizwan Qaisar, PhD Engineering Sales & Assistant Professor, College of Medicine
University of Sharjah
Matt Borkowski Engineering Sales & Marketing Manager,
Aurora Scientific Inc.
Aging and Bone Health
TUE, JUN 22, 2021 – UPCOMING
Join Dr. Joy Wu as she discusses the potential therapeutic approaches to age-related bone loss.
Osteoporosis is one of the most common degenerative diseases of aging. Half of adult women and one-quarter of adult men can expect to sustain an osteoporosis-related fracture. While current approaches to the treatment of osteoporosis can lower the risk of fracture, there is still no cure. In this webinar, Dr. Wu will review the pathophysiology of bone loss with aging, in particular the imbalance between bone formation by osteoblasts and bone resorption by osteoclasts. She will discuss stem cell sources of osteoblasts, anabolic signaling pathways, and targeting inflammation and senescence.
Joy Wu, MD, PhD Associate Professor of Medicine, Endocrinology
Special Vulnerabilities of the Aging Brain to Cognitive Decline and Dementia
WED, JUL 28, 2021 – UPCOMING
An abstract summary is coming soon!
Dr. De La Monte is a physician scientist who directs basic and translational research in the laboratory. She also performs clinical service work in Neuropathology. This activity includes teaching residents and students. Her research efforts are mainly focused on understanding the role of insulin and insulin-like growth factor resistance in relation to neurodegeneration caused by Alzheimer’s disease and chronic alcohol abuse.
From “Artificial” to “Real”: What 24/7 Home Cage Monitoring Teaches Us In Pre-Clinical Neurodegenerative Disease Models
WED, SEP 15, 2021 – UPCOMING
Artificial environments in which rodents are tested for their behavioral repertoire are still the gold standard for neuroscience research. However, increased concern of the validity of animal testing and the welfare of the laboratory animals is about to change this by moving to testing of behaviors in a setting that is familiar to the animals.
In this webinar Dr. Stefano Gaburro, Scientific Director a Tecniplast, will present an innovative non-invasive and scalable technique called Digital Ventilated Cage (DVC) that is meant to perform longitudinal studies for neurodegenerative disease models using long term monitoring of mice in a stress-free environment.
In the second part of the webinar, Dr. Brun Ulfhake from Karolinska Institutet will show how this technique can be used to study biorhythmicity (circadian and circannual) of small rodents and approaches to characterize and extract metrics of the spontaneous home-cage way of life for mice. These metrics may translate better to behavioral observations made in humans.
Dr. Bodine’s current research program is centered on the study of the neuromuscular system and its response and adaptation to various stressors, including aging. Skeletal muscle is a particularly interesting tissue because it interacts with and responds to numerous systems and signals to control movement, as well as, glucose homeostasis, metabolism, and thermogenesis. The recent focus of her research has been on identifying the cellular and molecular mechanisms that regulate skeletal muscle mass, especially under atrophy inducing conditions. Skeletal muscle loss occurs as the result of a variety of disparate conditions including: disuse, bed rest, spinal cord injury, neurodegeneration, diabetes, cancer, chronic glucocorticoid treatment and aging; and will affect every individual in their lifetime as the result of aging. The Bodine laboratory is interested in identifying the mechanisms responsible for muscle atrophy and determining strategies for preventing atrophy or accelerating recovery following a period of muscle loss. In the quest to understand muscle atrophy, Dr. Bodine has also investigated the mechanisms that regulate adaptive muscle growth, or hypertrophy, in adult animals. Finally, her lab is pursuing research to identify the molecular mediators of the health benefits of exercise.
Cardiac Inflammation and Repair Following Myocardial Infarction
WED, OCT 13, 2021 – UPCOMING
Following myocardial infarction (MI), the left ventricle (LV) undergoes a series of cardiac wound healing responses that involve both the stimulation of robust inflammation to clear necrotic myocytes and tissue debris and the induction of extracellular matrix (ECM) protein synthesis to generate an infarct scar. Collectively, this process in known as LV remodeling. Matrix metalloproteinase-9 (MMP-9) is a key regulator of LV remodeling post-MI, through direct effects on ECM turnover as well as indirect effects on the regulation of the major cell types that coordinate cardiac wound healing- namely the infiltrating leukocytes and the cardiac fibroblasts. We will discuss recent research that has expanded our understanding of MI LV remodeling, including recent proteomic advances focused on the ECM compartment to provide novel functional and translational insights. In summary, this webinar will provide an overview of how cardiac ECM research has evolved over the last decade and will provide insight into future directions that will drive our understanding of MMP directed cardiac ECM turnover after MI.
The American Physiological Society and InsideScientific welcome submissions from lab instrumentation manufacturers, service providers and CROs to plan and produce a “Technology & Methods” session for inclusion in our Physiology of Aging Webinar Series.
These sessions must focus on experimental planning, lab methodology, and best-practices with a goal of audience education and improving research process and outcomes. The program will accommodate 6-8 Technology & Methods sessions, and these sessions will be assigned to industry partners on a first-come-first-served basis. Technology & Methods sessions will be 45 minutes in duration, structured as a 30 minute instructional lecture followed by a live Q&A with the audience.
June 2, 2021
July 7, 2021
September 1, 2021
September 15, 2021
November 3, 2021
For additional information and to reserve a Technology & Methods Session as part of this program, please email Andy Henton at [email protected], or call +1 (226) 973-9168.
Select sponsorship and program support packages will be available for The Physiology of Aging Webinar Series.
Advertising and brand awareness packages will provide targeted exposure to registrants and webinar attendees. Again, a limited number of promotional packages are available for this program and will be confirmed on a first-come-first-served basis.